Current Report Filing (8-k)
02 October 2021 - 1:37AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 1, 2021 (September 30, 2021)
LUCKWEL
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
125
Cambridge Park Drive, Suite 301,Cambridge
|
|
MA
02140
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, include area code +1 (617) 430 5222
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section
1 - Registrant’s Business and Operations
Item
1.01 Entry into a Material Definitive Agreement
On
September 30, 2021, Luckwel Pharmaceuticals, Inc. (the “Company”) entered into a consultant agreement with Mr. Mark Corrao
to provide certain financial-related services. Pursuant to the agreement, Mr. Corrao will receive a monthly base consulting fee of $2,000
based on an hourly rate of $275. He will be eligible for a performance cash bonus of 50% of the base consulting fee in the event the
Company uplists onto the Nasdaq. Additionally, Mr. Corrao shall be entitled to an option to purchase 100,000 shares of the Company’s
common stock by/before November 2021 pursuant to the Company’s Stock Option and Equity Incentive Plan, which shall vest one year
thereafter provided (i) Mr. Corrao is still engaged as the Company’s consultant and (ii) the Company’s common stock has been
approved to be uplisted on the Nasdaq. The initial term of Mr. Corrao’s engagement shall expire on March 31, 2022, and thereafter
shall automatically renew for successive six-month terms unless terminated. If the Company terminates this agreement during the initial
term without cause, the aforesaid performance cash bonus shall be paid and the option shall immediately vest.
The
foregoing description of the principal terms of the consultant agreement is a general description only, does not purport to be complete,
and is qualified in its entirety by reference to the terms of the consultant attached hereto as Exhibit 10.1, which are incorporated
herein by this reference.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
LUCKWEL
PHARMACEUTICALS INC.
|
|
|
Date:
October 1, 2021
|
|
/s/
Kingrich Lee
|
|
Name:
|
Kingrich
Lee
|
|
Title:
|
Chief
Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From May 2024 to Jun 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Luckwel Pharmaceuticals Inc (GM) (OTCMarkets): 0 recent articles
More Luckwel Pharmaceuticals Inc. News Articles